Nasdaq Tower Nasdaq (Used with Permission Copyright 2014 NASDAQ OMX Group)

Organovo raised millions of dollars from investors to fuel its goal of developing 3D “bioprinted” human tissues for use in people with end-stage liver disease and other life-threatening illnesses.

But the San Diego company fell short of bringing its lead regenerative medicine program into clinical trials, and now it is charting a course as a vehicle for privately held cancer drug developer Tarveda Therapeutics to join the public markets.

Under the deal, announced Monday, Tarveda shareholders will own 75 percent of the combined company; Organovo shareholders, 25 percent. The boards of directors of the companies have approved the transaction,… Read more »